--- title: "Sermorelin | PepTracker Pro" url: https://peptrackerpro.com/peptides/sermorelin description: "A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Sermorelin Medium Evidence A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment. Aliases GRF 1-29 +1 more Evidence Medium Evidence Last Updated 2026-06-11 Reading Time 2 min ## What It Is Sermorelin is a synthetic peptide consisting of the first 29 amino acids of GHRH. It was previously FDA-approved under the brand name Geref for diagnosing and treating growth hormone deficiency in children. It stimulates the pituitary to release growth hormone in a pulsatile, physiological manner. Though the branded product was discontinued, it remains available through compounding pharmacies. In 2026, sermorelin continues to be one of the most commonly prescribed GHRH analogs at anti-aging and hormone optimization clinics, valued for its physiological pulsatile GH release pattern and established safety profile. It is frequently combined with ipamorelin (a GHRP) in clinical protocols to synergistically enhance GH output while minimizing cortisol and prolactin elevation. Sermorelin's shorter half-life compared to CJC-1295 (DAC) is viewed as both a limitation and an advantage — it better mimics the body's natural GH pulsatility. On April 15, 2026, the FDA removed sermorelin from Category 2 as part of a broader reclassification of 12 peptides, reinstating its eligibility for 503A bulk compounding under physician prescription. This regulatory shift followed HHS Secretary Robert F. Kennedy Jr.'s February 2026 announcement that most peptides placed on the Category 2 list in 2023 would be moved back to Category 1. In June 2026, telehealth company Noom finalized its acquisition of Tailor Made Compounding, a licensed 503A compounding pharmacy operating in 46 states, and announced plans to add sermorelin to its prescription formulary as part of an expansion into healthy-aging services — a sign that major consumer telehealth platforms are building regulated peptide supply chains ahead of the FDA's July 2026 PCAC compounding review. Also known as: GRF 1-29, Geref ## Regulatory Status Category 1 - Bulk Compounding Removed from Category 2 on April 15, 2026 as part of FDA reclassification of 12 peptides. Now eligible for 503A compounding with valid prescription. Previously FDA-approved under brand name Geref (discontinued). Effective: April 15, 2026 View FDA Source (https://ssrpinstitute.org/news/fda-announces-change-in-status-of-12-peptides/) ## Evidence Snapshot Medium Evidence Low Medium High ## Commonly Discussed Benefits Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Fat Loss: https://peptrackerpro.com/benefits/fat-loss Sleep: https://peptrackerpro.com/benefits/sleep Recovery: https://peptrackerpro.com/benefits/recovery Anti-Aging: https://peptrackerpro.com/benefits/anti-aging Researching Sermorelin? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=sermorelin) ## Safety & Cautions - Previously FDA-approved; branded product discontinued - Available through compounding pharmacies with prescription - Shorter half-life than newer GHRH analogs - Requires medical supervision ## Comparisons See how Sermorelin compares to related peptides: Sermorelin vs CJC-1295: https://peptrackerpro.com/compare/sermorelin-vs-cjc-1295 Sermorelin vs CJC-1295 (DAC): https://peptrackerpro.com/compare/sermorelin-vs-cjc-1295-dac Sermorelin vs Ipamorelin: https://peptrackerpro.com/compare/sermorelin-vs-ipamorelin Sermorelin vs Tesamorelin: https://peptrackerpro.com/compare/sermorelin-vs-tesamorelin Sermorelin vs Lonapegsomatropin: https://peptrackerpro.com/compare/sermorelin-vs-lonapegsomatropin ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Walker RF. — Sermorelin: a better approach to management of adult-onset growth hormone insufficiency. Clin Interv Aging. 2006 PubMed (https://pubmed.ncbi.nlm.nih.gov/) 2. [2] FDA Announces Change in Status of 12 Peptides - SSRP Institute. April 2026 PubMed (https://ssrpinstitute.org/news/fda-announces-change-in-status-of-12-peptides/) 3. [3] MobiHealthNews — Noom acquires compounding pharmacy to expand beyond weight loss PubMed (https://www.mobihealthnews.com/news/noom-acquires-compounding-pharmacy-expand-beyond-weight-loss) ### Keep researching in the app - Log Sermorelin to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=sermorelin Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### CJC-1295 Medium Evidence A growth hormone releasing hormone analog studied for stimulating growth hormone secretion. Muscle Growth (https://peptrackerpro.com/benefits/muscle-growth)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)Recovery (https://peptrackerpro.com/benefits/recovery)Sleep (https://peptrackerpro.com/benefits/sleep)+1 more View Details: https://peptrackerpro.com/peptides/cjc-1295 \+ Compare: https://peptrackerpro.com/compare?select=cjc-1295 Track in App: https://app.peptrackerpro.com/?add=cjc-1295 ### CJC-1295 (DAC) Medium Evidence A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification. View Details: https://peptrackerpro.com/peptides/cjc-1295-dac \+ Compare: https://peptrackerpro.com/compare?select=cjc-1295-dac Track in App: https://app.peptrackerpro.com/?add=cjc-1295-dac ### Ipamorelin Medium Evidence A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides. View Details: https://peptrackerpro.com/peptides/ipamorelin \+ Compare: https://peptrackerpro.com/compare?select=ipamorelin Track in App: https://app.peptrackerpro.com/?add=ipamorelin ### Tesamorelin High Evidence A GHRH analog FDA-approved for reducing visceral fat in HIV-associated lipodystrophy. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Growth: https://peptrackerpro.com/benefits/muscle-growth Metabolism: https://peptrackerpro.com/benefits/metabolism Anti-Aging: https://peptrackerpro.com/benefits/anti-aging View Details: https://peptrackerpro.com/peptides/tesamorelin \+ Compare: https://peptrackerpro.com/compare?select=tesamorelin Track in App: https://app.peptrackerpro.com/?add=tesamorelin ### Lonapegsomatropin High Evidence Lonapegsomatropin (brand name Skytrofa, developed as TransCon hGH by Ascendis Pharma) is a long-acting, once-weekly prodrug of human growth hormone (somatropin) approved to treat growth hormone deficiency (GHD). Unlike conventional recombinant growth hormone, which must be injected every day, lonapegsomatropin uses Ascendis's TransCon ("transient conjugation") technology to slowly release fully active, unmodified growth hormone from an inert carrier over the course of a week, so patients inject only once weekly. It is built from three parts - unmodified somatropin, a methoxypolyethylene glycol (mPEG) carrier that shields the hormone and extends its time in the body, and a TransCon linker that connects them and then self-cleaves at normal body pH and temperature to release native growth hormone at a controlled, predictable rate. The FDA first approved lonapegsomatropin in August 2021 for children one year and older with GHD (the pivotal Phase 3 heiGHt trial showed it was non-inferior and numerically superior to daily somatropin for annualized height velocity in treatment-naive children), and in July 2025 the FDA expanded approval to adults with GHD based on the Phase 3 foresiGHt trial, in which once-weekly TransCon hGH significantly reduced trunk fat and increased lean body mass versus placebo. It is administered subcutaneously with the SKYTROFA Auto-Injector using a single-dose, dual-chamber prefilled cartridge. Lonapegsomatropin is a regulated prescription medicine, not a supplement or research chemical, and shares the class safety profile of growth hormone therapy. endocrine: https://peptrackerpro.com/benefits/endocrine growth: https://peptrackerpro.com/benefits/growth Body Composition: https://peptrackerpro.com/benefits/body-composition metabolic: https://peptrackerpro.com/benefits/metabolic View Details: https://peptrackerpro.com/peptides/lonapegsomatropin \+ Compare: https://peptrackerpro.com/compare?select=lonapegsomatropin Track in App: https://app.peptrackerpro.com/?add=lonapegsomatropin ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Sermorelin", "description": "A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment.", "url": "https://peptrackerpro.com/peptides/sermorelin", "lastReviewed": "2026-06-11", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Sermorelin", "item": "https://peptrackerpro.com/peptides/sermorelin" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching growth hormone secretagogues?", "acceptedAnswer": { "@type": "Answer", "text": "Sermorelin is a research peptide studied in preclinical models. A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment." } }, { "@type": "Question", "name": "Those comparing GHRH analogs for body composition?", "acceptedAnswer": { "@type": "Answer", "text": "Sermorelin is a research peptide studied in preclinical models. A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment." } }, { "@type": "Question", "name": "Individuals exploring age-related GH decline?", "acceptedAnswer": { "@type": "Answer", "text": "Sermorelin is a research peptide studied in preclinical models. A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment." } } ] } ] ```